Key Highlights:
- Recursion Pharmaceuticals (RXRX, Financial) is set to announce its Q1 earnings on May 5, with analysts projecting a significant EPS decline.
- The stock's average one-year target price of $8.50 suggests a potential upside of nearly 49%.
- GuruFocus estimates the stock's GF Value at $13.21, indicating a substantial 131% upside potential.
Anticipated Q1 Earnings Report
Recursion Pharmaceuticals Inc. (RXRX) is gearing up to unveil its first-quarter earnings results on May 5. Analysts expect the company to report an earnings per share (EPS) of -$0.52, reflecting a significant 33.3% decline from the previous year. Despite this anticipated drop in earnings, the company is projected to achieve revenues of $18.08 million, which would mark a notable 31.1% increase.
Investor expectations have been adjusted accordingly, with three EPS estimates revised downward. On the brighter side, revenue estimates have seen one upward revision, indicating potential growth optimism.
Wall Street Analysts' Forecast
The consensus among six analysts suggests an average target price for Recursion Pharmaceuticals of $8.50. This target ranges from a high estimate of $11.00 to a low of $6.00, presenting an opportunity for a 48.86% upside from the current trading price of $5.71. Investors can explore detailed estimates on the Recursion Pharmaceuticals Inc (RXRX, Financial) Forecast page.
According to eight brokerage firms, the average brokerage recommendation for RXRX stands at 2.8, categorizing it as a "Hold." This rating is part of a scale where 1 denotes a Strong Buy, and 5 signifies a Sell.
The Strategic Potential of GF Value
GuruFocus provides an estimated GF Value for Recursion Pharmaceuticals at $13.21 over the next year, suggesting a remarkable upside potential of 131.35% from the current price of $5.71. The GF Value represents GuruFocus' assessment of the stock's fair value, calculated through historical multiples, past business growth, and future performance estimates.
For investors seeking a comprehensive analysis, further data is available on the Recursion Pharmaceuticals Inc (RXRX, Financial) Summary page.
